Stifel Raises Medtronic’s (MDT) Price Target After Positive Outlook on HUGO Robotic System

Core Insights - Medtronic plc (NYSE:MDT) is recognized as the world's largest manufacturer of biomedical devices and implantable technologies, operating through four primary divisions: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes [2]. Group 1: Price Target and Market Outlook - Stifel raised its price target on Medtronic from $90.00 to $105.00 while maintaining a Hold rating, following a visit to the company's HUGO robotic facility [3]. - The company is reportedly "confidently ready" to introduce its HUGO robotic system in the US, pending expected FDA approval by the end of fiscal 2026 [3]. - Medtronic's strong financial position enhances its prospects for expansion [3]. Group 2: HUGO Robotic System Development - Investors were provided with a detailed look at the HUGO system's development, including live demonstrations of Medtronic's digital ecosystem technologies [4]. - The company plans to adopt "a deliberate and thoughtful approach" for the introduction of the HUGO system to the US market after receiving FDA approval [4]. Group 3: Dividend Appeal - Medtronic's dividend adds to its investment appeal, as the company is close to achieving Dividend King status with 48 consecutive years of dividend increases [5].